Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.42 |
| ▸ | CYSLTR1 | Q9Y271 | 2/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12195814 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNAL3MBTL1KDM4EPPARG | |
| SCHEMBL12195813 | 1.00 | ALDH1A1 (0.47) | ALDH1A1LMNAL3MBTL1KDM4EPPARG | |
| SCHEMBL12250773 | 0.88 | L3MBTL1 (0.48) | ALDH1A1LMNAL3MBTL1KDM4EPPARG | |
| SCHEMBL74286 | 0.88 | L3MBTL1 (0.48) | ALDH1A1LMNAL3MBTL1KDM4EPPARG | |
| SCHEMBL12250772 | 0.88 | L3MBTL1 (0.48) | ALDH1A1LMNAL3MBTL1KDM4EPPARG | |
| SCHEMBL10419263 | 0.87 | KDM4E (0.57) | ALDH1A1LMNAL3MBTL1KDM4EATM | |
| SCHEMBL13894502 | 0.86 | ALDH1A1 (0.46) | ALDH1A1LMNAL3MBTL1KDM4EPPARG | |
| SCHEMBL21859970 | 0.84 | ALDH1A1 (0.47) | ALDH1A1L3MBTL1KDM4EPPARGATM | |
| SCHEMBL29429254 | 0.81 | ALDH1A1 (0.53) | ALDH1A1LMNAL3MBTL1KDM4EATM | |
| SCHEMBL30395472 | 0.81 | ALDH1A1 (0.53) | ALDH1A1LMNAL3MBTL1KDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-9949949-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | MALLINCKRODT PHARMA IP TRADING UNLIMITED COMPANY | 2017-02-16 | — | — | US | disclosed |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | OCERA THERAPEUTICS LLC | 2016-08-04 | — | — | US | disclosed |
| US-9371297-B2 | Macrocyclic ghrelin receptor modulators and methods of using the same | OCERA THERAPEUTICS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
| US-9181298-B2 | Intermediates for macrocyclic compounds | OCERA THERAPEUTICS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-8497242-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2013-07-30 | — | — | US | disclosed |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-09-06 | — | — | US | disclosed |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MARSAULT ERIC (CA) | 2012-06-28 | — | — | US | disclosed |
| US-8129561-B2 | Processes for intermediates for macrocyclic compounds | TRANZYME PHARMA INC. (CA) | 2012-03-06 | — | — | US | disclosed |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | IMC EXPLORATION COMPANY | 2011-10-06 | — | — | US | disclosed |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-09-24 | — | — | US | disclosed |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | TRANZYME PHARMA INC. | 2009-05-28 | — | — | US | disclosed |
| US-7521420-B2 | Macrocyclic antagonists of the motilin receptor | TRANZYME PHARMA, INC. (CA) | 2009-04-21 | — | — | US | disclosed |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | TRANZYME PHARMA INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10040751-B2 | Intermediates for macrocyclic compounds | MLNR, CCKAR, CHRM2 | ALDH1A1 2745/4885LMNA 3835/4885L3MBTL1 1727/4885 |
| US-20090137835-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ALDH1A1 2978/4885LMNA 3732/4885L3MBTL1 2098/4885 |
| US-20120165566-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ALDH1A1 2978/4885LMNA 3732/4885L3MBTL1 2098/4885 |
| US-20110245459-A1 | Processes for Intermediates for Macrocyclic Compounds | MLNR, CHRM2, CHRM1 | ALDH1A1 2978/4885LMNA 3732/4885L3MBTL1 2098/4885 |
| US-20160221927-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | ALDH1A1 2745/4885LMNA 3835/4885L3MBTL1 1727/4885 |
| US-20120226066-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ALDH1A1 2978/4885LMNA 3732/4885L3MBTL1 2098/4885 |
| US-20170042858-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | ALDH1A1 4245/4885LMNA 3523/4885L3MBTL1 1328/4885 |
| US-20090240027-A1 | INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CCKAR, CHRM2 | ALDH1A1 2729/4885LMNA 3791/4885L3MBTL1 1750/4885 |
| US-20120226067-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CCKAR | ALDH1A1 3005/4885LMNA 3526/4885L3MBTL1 2138/4885 |
| US-20080194672-A1 | MACROCYCLIC GHRELIN RECEPTOR MODULATORS AND METHODS OF USING THE SAME | GHSR, GHRHR, GIPR | ALDH1A1 4297/4885LMNA 3492/4885L3MBTL1 1333/4885 |
| US-20120226072-A1 | PROCESSES FOR INTERMEDIATES FOR MACROCYCLIC COMPOUNDS | MLNR, CHRM2, CHRM1 | ALDH1A1 2978/4885LMNA 3732/4885L3MBTL1 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.